I’ll be blunt28 Jun 2020 20:57
This is one of the easiest and most obvious multibaggers on the entire AIM market.
It’s difficult to see how the company could fail to produce some shareholder value from here now given the micro valuation of sub £3m. New, hopefully honest competent management clearly keen to align with shareholders interests. An established portfolio of drugs at various stages. A clear strategy of creating shareholder value earlier in drug development through collaborations, partnerships, licensing etc. Tighter control of costs.
This is, in many ways, a new animal. Out with the old corrupt - leave the past behind it mans nothing now. The future, at such a TINY valuation compared to other bio life science companies, is bright indeed.
Get on board. Fill your boots even. I know I am at this price.